Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Mar 30, 2010
Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic...
- Mar 25, 2010
Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will...
- Mar 12, 2010
Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces that it has entered into a licensing agreement with the Johns Hopkins University's...
- Mar 11, 2010
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic...
- Jan 19, 2010The DVTeamCare™ Hospital Award Provides National Recognition for Deep Vein Thrombosis Prevention Programs
The North American Thrombosis Forum (NATF), in coordination with Eisai Inc., announced today that three hospitals have been selected as recipients of the 2009 DVTeamCare Hospital Award. This new...
- Jan 6, 2010Eisai Completes Acquisition of AkaRx, Inc. and Continues Development of AKR-501 for Thrombocytopenia
Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces the successful completion of its acquisition of the biopharmaceutical company,...